Overview

Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)

Status:
NOT_YET_RECRUITING
Trial end date:
2031-09-30
Target enrollment:
Participant gender:
Summary
To find out if giving blinatumomab as injections under the skin and olverembatinib can help to control the disease in patients with Ph-positive ALL.
Phase:
PHASE2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Amgen
Ascentage Pharma Group Inc.
Treatments:
blinatumomab
olverembatinib